MHRA adds boxed warning and patient card for antidepressants after safety review
The MHRA is introducing new safety measures for all patients taking antidepressants, bringing suicidal thoughts and behaviours, along with persistent sexual dysfunction, into sharper focus in the materials that patients actually read. The changes follow a detailed review involving patients and families of how these risks are communicated in the patient information leaflets that accompany antidepressant medicines. A new boxed warning will be added to the patient information leaflet, alongside a patient card and a supporting safety leaflet that is due to become available in 2027.
For clinicians, the operational message is direct: these risks are not being newly discovered, but the regulator is treating them as important enough to require clearer, more prominent communication at the point of prescribing. The term post SSRI sexual dysfunction, or PSSD, will also be added to the leaflet for some antidepressants.
Suicidal thoughts need explicit discussion at initiation and dose change
Prescribers are being told to discuss the risk of suicidal thoughts and behaviours when starting an antidepressant, when changing the dose, or at the next review. Patients should be advised to seek urgent medical help if they develop new or worsening suicidal intent, particularly early in treatment or after a dose adjustment.
That timing matters at the bedside because the early treatment window is when patients and families are most likely to encounter abrupt changes in mood, activation, anxiety, or distress that can be misread as transient adjustment. In practical terms, the warning shifts suicide risk communication from a passive legal disclosure to an active monitoring plan.
Clinicians are also being reminded to follow relevant NICE guidance and to monitor patients regularly after treatment begins. The regulator’s message is not to withhold therapy, but to pair initiation with close follow-up, especially when the clinical picture already includes depression, anxiety, or prior self-harm risk.
Persistent sexual dysfunction is being given more visible wording
The updated materials also state that there is evidence some antidepressants are associated with sexual dysfunction and that symptoms may continue after treatment stops. Some patients refer to this as PSSD. The regulator’s language is careful but consequential: it does not frame the problem as rare, trivial, or purely transient, and it now requires clinicians to mention persistence explicitly when discussing harms and benefits.
This is a bedside issue as much as a regulatory one. Sexual adverse effects often drive silent nonadherence, delayed dose escalation, or abrupt discontinuation without clinical supervision. Once those symptoms are normalized in the discussion before treatment starts, patients are more likely to raise them early rather than abandon therapy quietly.
The advice to patients is equally direct: do not stop taking the medicine without first speaking to a healthcare professional. The leaflet update is designed to support a more informed conversation, not to discourage treatment that may still be beneficial for depression and related disorders.
New patient materials are meant to change how risk is communicated
The package now includes three layers of communication: a boxed warning in the patient information leaflet, a patient card, and a supporting safety leaflet that will be issued in 2027. Patients are also told to read the patient card and the leaflet that accompanies their medicine, because both contain essential information about treatment safety.
When the ancillary leaflet arrives, it is intended to help patients weigh benefits and risks of treatment options in discussion with their healthcare professional. The structure suggests a shift toward more deliberate shared decision-making, with repeated reinforcement at different points in the treatment pathway rather than a single warning buried in prescribing information.
Clinicians are also asked to report suspected adverse reactions linked to antidepressants through the Yellow Card scheme. That reporting route remains central to pharmacovigilance when symptoms are distressing, difficult to classify, or clinically significant enough to influence future regulatory decisions.
Clear instructions for urgent support and adverse event reporting
Patients who develop new or worsening suicidal thoughts, especially when starting or changing an antidepressant dose, are directed to seek urgent medical attention. The communication includes NHS 111, local mental health crisis teams, Samaritans on 116 123, and text support via SHOUT on 85258, with additional information on the NHS website.
The emphasis on urgent escalation reflects the reality that suicidal intent can intensify quickly, and families may be the first to notice behavioral change. In that setting, a leaflet is not a substitute for clinical review; it is a trigger for action.
At the same time, the MHRA states plainly that these are not new risks for these medicines. The change is in visibility, consistency, and timing of communication. Patients receiving antidepressants should now encounter the same safety message in the prescription discussion, in the leaflet, and in the follow-up plan.
What this means in routine practice
For day-to-day prescribing, the biggest change is not in drug selection alone. It is in the standard of counseling around treatment initiation, dose adjustment, and follow-up. Every clinician prescribing an antidepressant will need to be prepared to explain suicidal risk in the early phase of therapy and to discuss the possibility that sexual dysfunction may persist after discontinuation in some patients.
The regulator’s approach also reinforces the importance of documenting these conversations. Patients need to know what symptoms should prompt urgent contact, what side effects may affect adherence, and when to seek help rather than stopping treatment independently.
The pending 2027 ancillary leaflet will add another layer, but the immediate clinical task is already defined: stronger counseling, regular monitoring, and prompt adverse-event reporting. The unresolved question is how often these warnings will alter adherence, patient trust, and symptom disclosure once they are fully embedded in routine care.